Israel - anglès - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - tablets - salbutamol as sulfate 2 mg - salbutamol - salbutamol - relief of bronchospasm in bronchial asthma of all types, chronic bronchitis, emphysema.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. indications: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 2.4 mg/ml (equivalent: salbutamol, qty 2 mg/ml) - inhalation - excipient ingredients: sodium chloride; sulfuric acid; water for injections - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 1.2 mg/ml (equivalent: salbutamol, qty 1 mg/ml) - inhalation - excipient ingredients: sodium chloride; water for injections; sulfuric acid - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 6 mg/ml (equivalent: salbutamol, qty 5 mg/ml) - inhalation - excipient ingredients: purified water; benzalkonium chloride; sulfuric acid - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. indications: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Estats Units - anglès - NLM (National Library of Medicine)

unit dose services - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ventolin® hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients aged 4 years and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to any of the ingredients [see warnings and precautions (5.6), description (11)] . teratogenic effects: pregnancy category c. there are no adequate and well-controlled trials with ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relationship between albuterol use and congenital anomalies has not been established. animal reprod

Estats Units - anglès - NLM (National Library of Medicine)

a-s medication solutions - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ventolin hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients aged 4 years and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to any of the ingredients [see warnings and precautions (5.6), description (11)] . teratogenic effects pregnancy category c. there are no adequate and well-controlled trials with ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relationship between albuterol use and congenital anomalies has not been established. animal reproducti

Israel - anglès - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - syrup - salbutamol as sulfate 2 mg / 5 ml - salbutamol - salbutamol - relief of bronchospasm in bronchial asthma of all types,chronic bronchitis,efmphysema.

Israel - anglès - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - powder for inhalation - salbutamol as sulfate 200 mcg/dose - salbutamol - salbutamol - relief of bronchospasm in broncial asthma of all types, chronic, bronchitis and emphysema.